Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Two Menin Inhibitors Score in Early Leukemia Studies

  • Post author:PacConAdmin
  • Post published:December 12, 2022
  • Post category:Drug Industry Daily

Two potentially first-in-class small molecule oral agents induced complete remission in nearly 30 percent of patients with genetically induced leukemias generally associated with very poor prognoses, according to reports from…

Continue ReadingTwo Menin Inhibitors Score in Early Leukemia Studies

Amgen to Gain Eye Disease Blockbuster Drug in $28B Horizon Therapeutics Buyout

  • Post author:PacConAdmin
  • Post published:December 12, 2022
  • Post category:Drug Industry Daily

In the biggest pharmaceutical purchase announced this year, Amgen has inked a $28 billion deal with Horizon Therapeutics, gaining access to one blockbuster eye drug and two others that are…

Continue ReadingAmgen to Gain Eye Disease Blockbuster Drug in $28B Horizon Therapeutics Buyout

Guidance Clarifies How to Handle Aluminum Levels in Parenteral Nutrition Products

  • Post author:PacConAdmin
  • Post published:December 11, 2022
  • Post category:Drug Industry Daily

Manufacturers of parenteral nutrition (PN) products should determine the amount of aluminum in small-volume parenterals (SVP) as well as large-volume parenterals (LVP) to ensure PN products do not exceed the…

Continue ReadingGuidance Clarifies How to Handle Aluminum Levels in Parenteral Nutrition Products

Generics and API Manufacturers Aurobindo and Lupin Slapped With Lengthy 483s

  • Post author:PacConAdmin
  • Post published:December 11, 2022
  • Post category:Drug Industry Daily

The FDA issued a 10-observation Form 483 to Aurobindo’s Telangana, India, plant after a November visit, outlining several violations of current good manufacturing practices (cGMP). Source: Drug Industry Daily

Continue ReadingGenerics and API Manufacturers Aurobindo and Lupin Slapped With Lengthy 483s

Federal Judge Dismisses Many Cases Alleging Harm From Merck’s Shingles Vaccine

  • Post author:PacConAdmin
  • Post published:December 11, 2022
  • Post category:Drug Industry Daily

Four years into a multidistrict class action lawsuit, a federal court judge has dismissed 1,189 of the 2,000 lawsuits charging that Merck’s Zostavax shingles vaccine caused either the disease or…

Continue ReadingFederal Judge Dismisses Many Cases Alleging Harm From Merck’s Shingles Vaccine

Califf Projects Cell, Gene Therapies Will Drive Growth Over Next Five Years

  • Post author:PacConAdmin
  • Post published:December 11, 2022
  • Post category:Drug Industry Daily

FDA Commissioner Robert Califf predicts the agency’s largest area of expansion over the next five years will be in the regulatory apparatus for reviewing cell, regenerative and gene therapies. Source:…

Continue ReadingCaliff Projects Cell, Gene Therapies Will Drive Growth Over Next Five Years

FDA Proposes More Detailed Annual Reporting for INDs

  • Post author:PacConAdmin
  • Post published:December 8, 2022
  • Post category:Drug Industry Daily

The FDA has issued two proposed rules on investigational new drug applications (IND) that would require more detailed IND reports and exemptions for clinical trials for drug uses of a…

Continue ReadingFDA Proposes More Detailed Annual Reporting for INDs

FDA Places Sun Pharmaceutical on Import Alert Over cGMP Problems

  • Post author:PacConAdmin
  • Post published:December 8, 2022
  • Post category:Drug Industry Daily

The FDA has added a Sun Pharmaceutical facility in Gujarat, India, to an import alert following an agency inspection, but is exempting 14 products to avoid potential shortages. Source: Drug…

Continue ReadingFDA Places Sun Pharmaceutical on Import Alert Over cGMP Problems

Untitled Letter Warns Valisure About Pharmacy-Related Lapses

  • Post author:PacConAdmin
  • Post published:December 8, 2022
  • Post category:Drug Industry Daily

The FDA rapped independent testing lab Valisure in an untitled letter for violating the Drug Supply Chain Security Act (DSCSA) and for “methodological deficiencies” in its testing protocols, disputing the…

Continue ReadingUntitled Letter Warns Valisure About Pharmacy-Related Lapses

FDA Targets Specific Homeopathic Drug Categories in Final Guidance

  • Post author:PacConAdmin
  • Post published:December 8, 2022
  • Post category:Drug Industry Daily

The FDA plans to prioritize its enforcement and regulatory actions against specific homeopathic drug categories that pose a significant risk to public health, the agency said in a final guidance.…

Continue ReadingFDA Targets Specific Homeopathic Drug Categories in Final Guidance
  • Go to the previous page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.